𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Peginterferon Alfa-2a/Ribavirin for 48 or 72 Weeks in Hepatitis C Genotypes 1 and 4 Patients With Slow Virologic Response

✍ Scribed by Peter Ferenci; Hermann Laferl; Thomas–Matthias Scherzer; Andreas Maieron; Harald Hofer; Rudolf Stauber; Michael Gschwantler; Harald Brunner; Christoph Wenisch; Martin Bischof; Michael Strasser; Christian Datz; Wolfgang Vogel; Karin Löschenberger; Petra Steindl–Munda

Book ID
119761264
Publisher
Elsevier Science
Year
2010
Tongue
English
Weight
1020 KB
Volume
138
Category
Article
ISSN
0016-5085

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Randomized trial of peginterferon alfa-2
Randomized trial of peginterferon alfa-2b and ribavirin for 48 or 72 weeks in patients with hepatitis C virus genotype 1 and slow virologic response
✍ Maria Buti; Yoav Lurie; Natalia G. Zakharova; Natalia P. Blokhina; Andrzej Horba 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 197 KB 👁 2 views

The benefit of extending treatment duration with peginterferon (PEG-IFN) and ribavirin (RBV) from 48 weeks to 72 weeks for patients with chronic hepatitis C genotype 1 infection has not been well established. In this prospective, international, open-label, randomized, multicenter study, 1,428 treatm